Upon conclusion of this program, participants should be able to:

• Provide an update in key clinical areas of hematology, oncology, palliative care, surgical oncology and radiation oncology
• Identify the importance of early referral to palliative care
• Demonstrate the role of sipuleucel-T in refractory metastatic prostate cancer
• Assess the importance of risk stratification in multiple myeloma and apply it to selection of therapy
• Explain the EGFR mutation and its influence on therapy

Attendance at this Mayo course does not indicate nor guarantee competence or proficiency in the performance of any procedures which may be discussed or taught in this course.